Brain

GlassView Taps Amazon Ads’ Stellantis US Agency & Enterprise Lead as VP, Client Partnerships

NEW YORK, July 19, 2024 /PRNewswire/ -- With a 20 year career in producing data-driven solutions for clients at Amazon…

6 months ago

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

July 19, 2024 Biodexa Pharmaceuticals PLC Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals…

6 months ago

New Research on Climate Change, Gut Health, and Socioeconomic Status’ Impact on Stroke and Aneurysm Care to Be Presented at Society of NeuroInterventional Surgery’s 21st Annual Meeting

COLORADO SPRINGS, Colo., July 18, 2024 /PRNewswire/ -- Neurointerventional surgeons from across the globe will gather at the Society of…

6 months ago

K2 Laboratory Obtains NDC Codes for Two Investigational Drugs

K2 Laboratory recently announced that its two investigational drugs, Brain Rehabilitation oral solution and Telomerase Inhibitor oral solution, have successfully…

6 months ago

Apollo Biowellness f/k/a Resonate Blends Has Engaged LB Equity Health and Wellness Fund, a Division of The Lucas Group

North Bergen, New Jersey--(Newsfile Corp. - July 18, 2024) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company") is pleased…

6 months ago

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

‘Breaking Barriers’ Coalition Formed to Address Opioid Use Disorder in the USA Nexalin CEO Mark White Participates in Inaugural Meeting…

6 months ago

Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

As the third and final clinical site, Memorial Sloan Kettering Cancer Center joins Brigham Women’s Hospital and Baptist Hospital of…

6 months ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to…

6 months ago

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar…

6 months ago

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic…

6 months ago